• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home Weekly Rewinds

2 Minute Medicine Rewind April 14, 2025

bySimon Pan, MDandAlex Chan
April 14, 2025
in Weekly Rewinds
Reading Time: 6 mins read
2 Minute Medicine Rewind April 14, 2025
Share on FacebookShare on TwitterShare on LinkedIn

Yoga or Strengthening Exercise for Knee Osteoarthritis

1. In patients with knee osteoarthritis (OA), yoga did not significantly reduce knee pain compared to those performing strengthening exercises.

Yoga was non-inferior compared to strengthening exercises for patients with knee osteoarthritis with similar knee symptoms, quality of life and depression observed in both groups. 

Evidence Rating Level: 1 (Excellent)

Exercise therapy is currently recommended as first-line therapy for OA by several international guidelines. However, differences in the effectiveness of different forms of exercise have not been well explored in the management of knee OA. This study therefore sought to compare the effectiveness of yoga and strengthening exercises in patients with OA. Between June 2021 and June 2022, 117 participants (mean[SD] age, 62.5[8.3] years; 72.6% female) with knee OA from Australia were randomized to either a yoga program (n = 58) or a strengthening program (n = 59). Both programs took place across 24 weeks and involved 3 sessions per week of each respective exercise type. Participants were assessed at 4 week intervals for visual analog scale (VAS) knee pain and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Over 12 weeks, there was no significant between-group differences in mean VAS knee pain (between-group difference, −1.1 mm [95% CI, −7.8 to 5.7 mm]; P = .76; Cohen d, −0.2 [95% CI, −1.6 to 1.2]). A similar trend was observed over 24 weeks with no significant between-group differences in mean VAS knee pain (between-group difference: −5.8 mm [95% CI, −12.9 to 1.2 mm]; P = .11; Cohen d, −1.1 [95% CI, −2.5 to 0.3]). Over 24 weeks, there was a modest difference between groups in favour of yoga for WOMAC pain (between-group difference, −44.5 mm [95% CI, −70.7 to −18.3 mm]). Overall, this study found that yoga was similar in effectiveness to strengthening exercises for patients with knee OA. 

 

RELATED REPORTS

Lower resident board pass rates in private-equity backed emergency physician groups

2 Minute Medicine Rewind November 2, 2026

Epinephrine vs Norepinephrine as Initial Treatment in Children With Septic Shock

1. Epinephrine was associated with greater 30-day mortality compared to norepinephrine in the management of septic shock in pediatric patients.

Evidence Rating Level: 2 (Good)

Vasoactive agents remain the therapeutic option of choice in the management of septic shock in children who have not adequately responded to intravenous fluid resuscitation alone. In adults, norepinephrine remains the clear first line vasoactive agent of choice. However, there are few studies comparing the effectiveness of epinephrine and norepinephrine in children with septic shock. This study therefore sought to investigate outcomes in children with septic shock who were treated with either agent. 231 children (median[IQR] age, 11.4[5.6-15.4] years); 54.6% female) from the Boston Children’s Hospital with septic shock who were treated with epinephrine (n = 147) or norepinephrine (n = 84) were included in the analysis. The primary outcome of the study was MAKE30 which was a composite outcome including death or renal function-related outcomes such as persistent kidney dysfunction by 30 days of hospital discharge, whichever occurred first. Secondary outcomes included 30 day in-hospital mortality. There was no statistically significant difference in the number of children who met MAKE30 between children who received epinephrine or norepinephrine (6.1% vs 3.6% respectively). Epinephrine was associated with greater 30-day mortality compared to norepinephrine  (3.7 vs 0%; risk difference: 3.7%; 95% CI, 0.2% to 7.2%). Overall, this study found that among children with septic shock requiring vasoactive agents, epinephrine was associated with greater 30-day mortality compared to norepinephrine. 

 

Heterogeneous treatment effects of stress ulcer prophylaxis among ICU patients at risk for gastrointestinal bleeding

1. In patients admitted to the intensive care unit (ICU) with at least one risk factor for clinically significant gastrointestinal bleeding (GIB), the impact of stress ulcer prophylaxis (SUP) on 28-day mortality was greatest in those who were younger, had chronic liver disease, coagulopathy or malignancy. 

Evidence Rating Level: 2 (Good)

While GIB can contribute to critical illness or death, SUP may also increase the rate of adverse events such that it is difficult to delineate whether benefits of SUP justify its application in such patients. A previous clinical trial has shown benefits for SUP in ICU patients with risk factors for GIB. However, significant heterogeneity in treatment effect was observed depending on patient characteristics. This retrospective cohort study therefore sought to identify which patients would benefit most from SUP. Records of 25,475 patients (median[IQR] age, 66[55-77] years) with at least 1 risk factor for GIB were obtained from a comprehensive database from the Beth Israel Deaconess Medical Centre, Boston and analyzed for 28-day mortality after ICU entry. When analyzed based on subgroups, the impact of SUP on 28-day mortality was markedly different in patients older than 77 compared to other age groups (posterior probability of difference in OR, 99.3%), in patients with liver disease compared to those without (median OR, 0.87 vs 1.07; posterior probability of difference in OR, 99.9%), in patients with coagulopathy compared to those without (median OR, 0.95 vs 1.09; posterior probability of difference in OR, 92.1%) and in those with malignancy compared to those without (median OR 0.57 vs 1.20, posterior probability of difference in OR, 100%). Overall, this study found that among patients admitted to ICU with at least one risk factor for clinically significant GIB, the impact of SUB on 28-day mortality was greatest in younger patients and patients who had chronic liver disease, coagulopathy or malignancy.

 

Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study

1. In postmenopausal patients with ulcerative colitis (UC) or Crohn’s disease (CD), approximately one-third had osteoporosis while approximately 40% had osteopenia.

2. In men aged over 50 years with UC or CD, approximately 13% had osteoporosis while approximately 50% had osteopenia. 

Evidence Rating Level: 2 (Good)

Osteopenia and osteoporosis are diseases that are well-known to occur commonly in those with inflammatory bowel disease (IBD). However, the prevalence of osteopenia and osteoporosis at IBD diagnosis has not been well characterized, and bone mineral density (BMD) testing remains underutilized in these patients. This prospective cohort study therefore sought to determine the incidence of osteopenia and osteoporosis at IBD diagnosis. 209 and 141 patients with a new diagnosis of UC (median[IQR] age, 44[28-57]; 53.1% female) and CD (median age[IQR], 36[25-54]; 46.1% female) from Copenhagen were included and assessed for osteopenia and osteoporosis via BMD testing using dual-energy X-ray absorptiometry (DEXA). Among postmenopausal women with a new diagnosis of UC and CD, 35.7% (15/42) and 28.6% (6/21) were diagnosed with osteoporosis respectively. Among males aged above 50 years with a new diagnosis of UC and CD, 13.2% (5/38) and 12.5% (3/24) were diagnosed with osteoporosis respectively. The incidence of osteopenia in postmenopausal women with newly diagnosed UC and CD was 40.5% (17/4) and 38.1% (8/21) respectively, while in men aged above 50 with newly diagnosed UC and CD it was 44.7% (17/38) and 50.0% (12/24) respectively. Overall, this study showed that postmenopausal women and men aged over 50 with a new diagnosis of UC and CD experience much higher rates of osteopenia and osteoporosis compared to those without UC and CD. 

 

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer

1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the risk of death compared to the investigator’s choice of chemotherapy in the management of Kirsten rat sarcoma viral oncogene homologue (KRAS) glycine-to-cysteine mutation at codon 12 (KRAS G12C) colorectal cancer.

Evidence Rating Level: 1 (Excellent)

Currently, the management of KRAS-mutated colorectal cancer remains limited to chemotherapy with a lack of targeted therapeutic options available. CodeBreak 300 was a randomized, phase III clinical trial which evaluated the efficacy of sotorasib, an irreversible KRAS G12C inhibitor, in combination with panatimumab compared to the investigator’s choice of standard-care trifluridine/tipiracil or regorafinib. This study presents the final analysis of overall survival (OS) of CodeBreak 300. 160 patients with KRAS G12C chemorefractory metastatic colorectal cancer (mCRC) were randomly assigned to receive either sotorasib 960 mg-panatimumab (n = 53), sotorasib 240 mg-panatimumab (n = 53) or investigator’s choice (n = 54). The estimated hazard ratio (HR) for OS was 0.83 (95% CI, 0.49 to 1.39; descriptive two-sided P = .50) with sotorasib 240 mg-panatimumab and 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20 v statistically significance threshold 0.01875) with sotorasib 960 mg-panatimumab. The overall response rates (ORR) across the sotorasib 960 mg-panatimumab, sotorasib 240 mg-panatimumab, and investigator’s choice groups were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9). Overall, this study found that while there was no statistically significant difference in OS between each of the groups, the use of sotorasib 960 mg plus panitumumab may have a 30% relative risk reduction in the risk of death compared to the use of trifluridine/tipiracil or regorafinib. 

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: chronic diseasecritical careemergency medicinepediatricsrewind
Previous Post

Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:

Next Post

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

RelatedReports

A female medical resident reviews documents with a clock showing the passage of time in a hospital setting, symbolizing long duty hours.
All Specialties

Lower resident board pass rates in private-equity backed emergency physician groups

November 11, 2026
Migraine collage of a young woman resting with eyes closed beside a teal zigzag ribbon, a curtained window and water
Weekly Rewinds

2 Minute Medicine Rewind November 2, 2026

November 2, 2026
A graphic featuring a heart, kidney, bladder, stethoscope, and an ultrasound machine, arranged in a flower-like design on a light blue background.
Weekly Rewinds

2 Minute Medicine Rewind October 5th, 2026

October 5, 2026
A depiction of a heart, a vaccine vial, and a COVID-19 virus, with an ECG waveform in the background.
Artificial Intelligence

Artificial intelligence (AI)-triggered rapid response notifications were associated with lower mortality among inpatients

October 2, 2026
Next Post
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Prescription medicines collage: a mortar and pestle, a blister pack of white tablets, teal capsules and a glass beaker

Increased tirzepatide use for glycemic and weight control since United States market entry

Patient communication collage: two empty armchairs facing each other, a side table with two cups and a floor lamp

Poor communication closely associated with patient safety incidents

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
  • CDC reports 5,412 confirmed measles cases in the United States in 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.